Fig. 3

IL-33 induces ILC2 egress through down-regulating CXCR4. A Expression and B mean fluorescence intensity (MFI) of CXCR4 on BM ILC2p from WT and Il33^−/− mice in response to sham surgery or CLP for 24 h analyzed by flow cytometry (n = 4–5 mice/group). C Expression and D MFI of CXCR4 on lung ILC2 from WT and Il33^−/− mice after sham surgery or CLP for 24 h (n = 4–5 mice/group). E, F Expression of CXCR4, shown by flow cytometry and bar graph, on BM ILC2p at 24 h after LPS (1 μg/ml) with or without rmIL-33 (50 ng/ml) treatment and IL-2 (10 ng/ml), IL-7 (10 ng/ml) (n = 3 per group). G Representative flow cytometry plots and H & I bar graphs showing BM ILC2p percentages and absolute number of Sham + PBS, sham + AMD3100, CLP + PBS, and CLP + AMD3100 in WT, Il33^−/− mice. PBS (100 μl) or AMD3100 [3.2 mg/kg B.W. in 100 μl PBS] were injected intravenously (i.v.) 30 min prior to CLP, and CLP for 24 h (n = 4–5 mice/group). J The percentage of number in each group to sham surgery mice treated with PBS. Number in BM of sham + PBS mice normalized to 100%. Data shown are the mean ± SEM. *P < 0.05, **P < 0.01, NS = not significant